云知声(09678)大力尝试新的可持续商业模式并积极探索新型项目机会 合景泰富集团(01813)8月预售额为6.11亿元，同比减少13.9% 广汽集团(02238)8月汽车销量13.57万辆 同比下降8.43% 中梁控股(02772)前8个月累计合约销售额约82.9亿元 同比减少32.71% 协合新能源(00182)8月权益发电量总计507.64GWh，同比增长6.07% 【重大事项】： 君实生物(01877)：抗IL-17A单抗治疗中重度斑块状银屑病的Ⅲ期临床研究达到主要研究终点 和黄医药(00013)将于2025年世界肺癌大会和中国临床肿瘤学会2025年年会公布自主研发的化合物的数 项研究的最新数据 映恩生物-B(09606)：DB-1303/BNT323用于HER2阳性不可切除或转移性乳腺癌患者的III期临床试验达 到主要研究终点 恒瑞医药(01276)拟将1 类创新药 HRS-1893项目有偿许可给 Braveheart Bio以拓展海外市场 【财务数据】： 正荣地产(06158)前8个月累计合约销售金额约29.91亿元 同比减少30.8% ...

赛沃替尼用于治疗非小细胞肺癌的SACHI研究、SAVANNAH研究以及一项IIIb期验证性研究的最新分析 结果将于2025年世界肺癌大会公布。赛沃替尼是一种强效、高选择性的口服MET酪氨酸激酶抑制剂 (TKI)，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。 格隆汇9月5日｜和黄医药(0013.HK)公布，将于9月6日-9日在西班牙巴塞隆拿召开的2025年世界肺癌大 会(WCLC)，以及9月10-14日在中国济南召开的中国临床肿瘤学会(CSCO)2025年年会上公布和黄医药自 主研发的化合物的数项研究的最新及更新后的数据。 ...

Core Viewpoint - HCM's stock rose over 6% to $15.76 following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Conferences - HCM will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Key Research Studies - The latest analysis results of the SACHI and SAVANNAH studies, which evaluate the efficacy of Savolitinib for treating non-small cell lung cancer, will be presented at the WCLC [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel selective and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO meeting [1]

Core Viewpoint - HCM's stock price increased by over 6% to $15.76 following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - HCM will present updated data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for non-small cell lung cancer, will be presented at the WCLC [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel selective and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO meeting [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 5%, currently at 24.68 HKD with a trading volume of 112 million HKD, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib (赛沃替尼), will be presented at the WCLC. Savolitinib is a potent and selective oral MET tyrosine kinase inhibitor co-developed by AstraZeneca and Hutchison China MediTech [1] - The first human Phase I clinical trial data of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO annual meeting [1]

Core Viewpoint - Hutchison China MediTech (00013) saw a stock increase of over 5%, reaching HKD 24.68 with a trading volume of HKD 112 million, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for non-small cell lung cancer, will be disclosed at the WCLC [1] - HMPL-653, a novel selective and potent CSF-1R inhibitor, will have its first human Phase I clinical trial data in Chinese patients with tenosynovial giant cell tumors presented at the CSCO annual meeting [1]

Core Insights - Hutchison China MediTech Limited (Chi-Med) will present updated data on several of its self-developed compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona and the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China [1] Group 1: Upcoming Conferences - The 2025 WCLC will take place from September 6 to 9 in Barcelona, Spain [1] - The 2025 CSCO Annual Meeting will be held from September 10 to 14 in Jinan, China [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for treating non-small cell lung cancer, will be presented at the WCLC [1] - Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and Chi-Med, with commercialization by AstraZeneca [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be presented for the first time at the CSCO Annual Meeting [1]

赛沃替尼用于治疗非小细胞肺癌的SACHI研究、SAVANNAH研究以及一项Ib期验证性研究的最新分析 结果将于2025年世界肺癌大会公布。赛沃替尼是一种强效、高选择性的口服MET酪氨酸激酶抑制剂 (ГTKI)，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。 格隆汇9月5日丨和黄医药(00013.HK)宣布将于2025年9月6日至9日在西班牙巴塞罗那召开的2025年世界 肺癌大会(WCLC)，以及2025年9月10至14日在中国济南召开的中国临床肿瘤学会("CSCO")2025年年会 上公布和黄医药自主研发的化合物的数项研究的最新及更新后的敷据。 ...

Core Insights - Hutchison China MediTech Limited (HCM) will present updated data on its proprietary compounds at two major conferences in September 2025, specifically the World Lung Cancer Conference (WCLC) in Barcelona and the Chinese Society of Clinical Oncology (CSCO) annual meeting in Jinan, China [1] Group 1: Upcoming Presentations - HCM will showcase the latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for the treatment of non-small cell lung cancer at the WCLC [1] - The first human Phase I clinical trial data for HMPL-653, a novel selective and potent CSF-1R inhibitor, will be presented at the CSCO annual meeting [1] Group 2: Drug Development - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and HCM, with AstraZeneca responsible for commercialization [1]

Core Insights - HUTCHMED will present new and updated data from several studies at the 2025 World Conference on Lung Cancer (WCLC) and the Chinese Society of Clinical Oncology (CSCO) Annual Meeting [1][2][3] Group 1: WCLC Presentations - Updated analysis from savolitinib's studies, including SACHI, SAVANNAH, and a Phase IIIb confirmatory study in non-small cell lung cancer (NSCLC) patients, will be presented [2] - Specific presentations include: - "Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and/or Amp NSCLC" by Christina Baik on September 7, 2025 [2] - "Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy" by Yongfeng Yu on September 9, 2025 [2] - Insights from the SACHI study regarding frontline treatment duration in MET-Amplified NSCLC after third-generation EGFR-TKI failure [2] Group 2: CSCO Annual Meeting Presentations - Clinical data of HMPL-653, a novel CSF-1R inhibitor, will be presented for the first time at the CSCO Annual Meeting [3] - Specific presentations include: - A first-in-human Phase I study of HMPL-653 in patients with tenosynovial giant cell tumor by Xiaohui Niu on September 12, 2025 [3] - Updated efficacy and safety data for Fruquintinib in various cancer types, including metastatic or unresectable non-clear cell renal cell carcinoma and advanced esophageal squamous cell carcinoma [3][4] Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases [5] - The company has successfully marketed its first three medicines in China, with the first also approved in the US, Europe, and Japan [5]